Summit on Anti-SARS-CoV-2 Antibodies for Treatment and Prevention of COVID-19: Lessons Learned and Remaining Questions

Date & Time: June 15, 2021, 11:00 AM – 4:00 PM EDT  Broadcast Live at: videocast.nih.gov/watch=42078
No Registration Required – Open for Public Viewing

Purpose: To summarize current knowledge and lessons learned on clinically relevant anti-SARS-CoV-2 antibodies for the treatment and/or prevention of COVID-19 and to identify key unanswered scientific questions to catalyze antibody clinical development and implementation.

Agenda

11:00 AM – 11:15 AM  Introductory Comments
- Dr. Francis S. Collins – Director, National Institutes of Health
- Dr. Janet Woodcock – Acting Commissioner, US Food and Drug Administration
- Dr. Anthony S. Fauci – Director, National Institute of Allergy and Infectious Diseases

11:15 AM – 12:30 PM  State of the Science Presentations
- Convalescent plasma and hyperimmune globulin: Dr. Peter Marks – US Food and Drug Administration
- Antibodies for COVID-19 prevention: Dr. Myron S. Cohen – University of North Carolina at Chapel Hill
- Antibodies for COVID-19 treatment:
  - Dr. Kara Chew – University of California, Los Angeles
  - Dr. Jens Lundgren – Rigshospitalet, University of Copenhagen
- Mutations/variants of concern: Dr. Bette Korber – Los Alamos National Laboratory

12:30 PM – 1:30 PM  Session I: Mechanisms of Action of Functional Antibodies that Neutralize SARS-CoV-2 and/or Eliminate SARS-CoV-2 Infected Cells
- Presenter: Dr. Erica O. Saphire – La Jolla Institute for Immunology
- Moderator: Dr. Adrian McDermott – National Institute of Allergy and Infectious Diseases
- Panelists:
  - Dr. Christopher Barnes – Stanford University
  - Dr. Michael Diamond – Washington University in St. Louis
  - Dr. David Montefiori – Duke University
  - Dr. Penny Moore – University of the Witwatersrand
  - Dr. Rachel Liberatore – RenBio
  - Dr. Laura Walker – Adagio Therapeutics

1:30 PM – 1:45 PM  -Break-

Sponsored by the National Institute of Allergy and Infectious Diseases and the NIH Office of the Director
1:45 PM – 2:45 PM  Session II: Preclinical Delivery, Pharmacology, and Efficacy of Anti-SARS-CoV-2 Antibodies
  • Presenter: Dr. Ralph Baric – University of North Carolina at Chapel Hill
  • Moderator: Dr. Connie Schmaljohn - National Institute of Allergy and Infectious Diseases
  • Panelists:
    ▪ Dr. Christopher Ellis – US Food and Drug Administration
    ▪ Dr. Tom Hope – Northwestern University
    ▪ Dr. Kevin Saunders – Duke University
    ▪ Dr. Skip Virgin – Vir Biotechnology
    ▪ Dr. Emmie de Wit - National Institute of Allergy and Infectious Diseases

2:45 PM – 3:45 PM  Session III: Real World Clinical Use of Anti-SARS-CoV-2 Antibodies
  • Presenter: Dr. Katharine Bar – University of Pennsylvania
  • Moderator: Dr. Rajesh Gandhi – Massachusetts General Hospital
  • Panelists:
    ▪ Dr. Ada Adimora – University of North Carolina at Chapel Hill
    ▪ Dr. Judith Currier – University of California Los Angeles
    ▪ Dr. Fred Korley – University of Michigan
    ▪ Dr. Meagan O’Brien – Regeneron
    ▪ Dr. John Redd – HHS Office of the Assistant Secretary for Preparedness and Response
    ▪ Dr. Mark Williams – Lilly

3:45 PM – 4:00 PM  Wrap Up and Closing Comments
  • Dr. Adrian McDermott – National Institute of Allergy and Infectious Diseases
  • Dr. Connie Schmaljohn - National Institute of Allergy and Infectious Diseases
  • Dr. Rajesh Gandhi – Massachusetts General Hospital
  • Dr. Francis S. Collins – Director, National Institutes of Health